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Abstract
Death receptor-induced programmed necrosis is regarded as a secondary death mechanism dominating only in cells that
cannot properly induce caspase-dependent apoptosis. Here, we show that in cells lacking TGFb-activated Kinase-1 (TAK1)
expression, catalytically active Receptor Interacting Protein 1 (RIP1)-dependent programmed necrosis overrides apoptotic
processes following Tumor Necrosis Factor-a (TNFa) stimulation and results in rapid cell death. Importantly, the activation of
the caspase cascade and caspase-8-mediated RIP1 cleavage in TNFa-stimulated TAK1 deficient cells is not sufficient to
prevent RIP1-dependent necrosome formation and subsequent programmed necrosis. Our results demonstrate that TAK1
acts independently of its kinase activity to prevent the premature dissociation of ubiquitinated-RIP1 from TNFa-stimulated
TNF-receptor I and also to inhibit the formation of TNFa-induced necrosome complex consisting of RIP1, RIP3, FADD,
caspase-8 and cFLIPL. The surprising prevalence of catalytically active RIP1-dependent programmed necrosis over apoptosis
despite ongoing caspase activity implicates a complex regulatory mechanism governing the decision between both cell
death pathways following death receptor stimulation.
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Introduction
TNFa is a pleiotropic cytokine regulating a variety of cellular
responses such as proliferation, differentiation, and cell death. By
binding to TNF receptor I (TNF-RI), a death receptor superfamily
member, TNFa induces the formation of the plasma membrane-
associated complex-I, including TRADD, TRAF2/5, cIAP1/2
and RIP1. Within complex-I, RIP1 is ubiquitinated depending on
TRAF2/5 and cIAP1/2 and polybuiquitinated RIP1 (Ubi-RIP1)
recruits TAK1 (TAK1/TAB2/TAB3) and IKK (IKKa/IKKb/
NEMO) kinase complexes. Then, auto-activated TAK1 phos-
phorylates and activates IKKb, facilitating IKKb-mediated IkBa
degradation and downstream NF-kB activation [1,2].
Ligation of TNF-RI by TNFa also leads to the assembly of a
second, cytoplasmic multiprotein complex. Deubiquitination of
RIP1 is prerequisite for the formation of complex-II comprising
RIP1, RIP3, FADD and caspase-8, which is then activated by
auto-cleavage and initiates apoptosis. Caspase-8 also cleaves RIP1
and inactivates it within complex-II [1,3]. TNFa-induced
apoptosis is mainly studied in the absence of de novo protein
synthesis or in cells lacking crucial activators of the NF-kB
pathway, since cells that can trigger TNFa-dependent NF-kB
activation express multiple anti-apoptotic genes and block
complex-II-mediated apoptosis initiation [4,5,6,7].
TNFa-induced programmed necrosis, or necroptosis, is a
recently defined alternative cell death pathway absolutely
requiring RIP1 kinase activity and is described to dominate only
when dying cells cannot activate caspase-8 [1,3]. Under these
conditions, TNFa-induced complex-II acts as the pre-necrotic
‘necrosome’ complex, where catalytically active RIP1 and RIP3
trigger rapid reactive-oxygen-species (ROS) accumulation and
subsequent cell death with morphological features reminiscent of
necrosis [1,3,8,9,10]. The catalytic activity of RIP1 is required for
the formation of the necrosome complex [8]. Since RIP1 is
inactivated by caspase-8, prevention of RIP1 cleavage by caspase
inhibition is thought to be required for efficient death receptor-
mediated necrosis induction.
Recent studies indicated a role for cFLIPL, the catalytically
inactive homologue of caspase-8, in programmed necrosis
inhibition [11,12]. Hetero-dimerisation of caspase-8 and cFLIPL
was shown to be necessary for caspase-8 mediated protection from
necrosis [12]. However, depending on its expression level, cFLIPL
may inhibit or augment caspase-8 activity [13], hence its
mechanistic contribution in necrosis is not completely clear.
As TAK1 is a critical component of TNFa-induced NF-kB
activation, cells lacking TAK1 expression undergo cell death
following TNFa stimulation [14,15,16,17,18]. However, TAK1
knock-out (KO) cells are remarkably more sensitive to TNFa-
induced cytotoxicity than other types of cells that cannot activate
NF-kB [18,19]. In addition, TAK1 KO mice die at an earlier
embryonic stage than mice lacking IKKb or NEMO expression
[4,5,19,20]. This shows that TAK1 has additional, NF-kB-
independent functions during embryonic development. It has
been reported that TNFa stimulation of TAK1 KO keratinocytes
led to a ROS-mediated, rapid cell death [18]. Moreover, it has
recently been shown that in L929 cells, a murine fibrosarcoma cell
line that undergoes caspase-independent programmed necrosis
upon TNFa stimulation and is commonly used as a model system
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for this type of cell death, down-regulation of TAK1 augmented
the ongoing necrotic response [21]. Here, we dissect the molecular
mechanism of TNFa-induced death of TAK1 deficient cells and
show that ablation of TAK1 expression alone is sufficient for the
induction of TNFa-mediated programmed necrosis in cells that
are otherwise resistant to TNFa-induced cytotoxicity. We
identified RIP1 as a critical mediator of TNFa-induced ROS
accumulation and cell death in the absence of TAK1, indicating
the induction of the necrotic pathway. TAK1 mediated the
stabilization of polyubiquitinated RIP1 in complex-I and prohib-
ited RIP1-dependent rapid necrosis, unravelling a novel functional
connection between these two kinases in addition to their
established cooperation in TNFa-induced NF-kB signalling.
Moreover, our results demonstrated that RIP1 kinase activity-
dependent cell death proceeds even in the presence of ongoing
caspase activity.
Results and Discussion
TAK1 hinders TNFa-induced, RIP1-mediated rapid cell
death
To evaluate whether RIP1 plays a role in the death of TAK1
KO mouse embryonic fibroblasts (MEFs), cells were transfected
with two different RIP1-targeting siRNA constructs along with a
control siRNA. Loss of RIP1 completely prevented TNFa-induced
cell death after 2.5 hours of stimulation and provided major
protection after 6 hours (Fig. 1A). In addition, TNFa-induced
ROS accumulation in TAK1 KO MEFs could be fully prevented
by RIP1 down-regulation (Fig. 1B). A specific RIP1 kinase- and
programmed necrosis-inhibitor, Necrostatin-1 (Nec-1) [22,23],
and the ROS scavenger butylated hydroxyanisole (BHA) also
completely blocked TNFa-mediated cytotoxicity (Fig. 1C) [18].
Moreover, Nec-1 was as effective as BHA in blocking TNFa-
induced ROS accumulation in the absence of TAK1 (Fig. 1D).
Taken together, these experiments show that catalytically active
RIP1 is essential for TNFa-dependent, ROS-mediated rapid cell
death in the absence of TAK1, indicating the triggering of the
necrotic pathway.
Necrosis overrules apoptosis in TNFa-treated TAK1
deficient cells
Death receptor-mediated programmed necrosis has been
defined to predominate in the absence of caspase activity [1,3].
However, TNFa stimulation induced the cleavage of caspase-8,
caspase-3 and the caspase-8 target, RIP1 in TAK1 KO MEFs
(Fig. 2A), similar to previous observations made in keratino-
cytes [18]. Treatment of TAK1 KO MEFs with the pan-
caspase inhibitor zVAD-FMK completely abrogated caspase-8
and caspase-3 cleavage (Fig. 2B) as well as the cleavage of RIP1
and the caspase-3 target, PARP1 (Fig. S1A), nevertheless
provided only minor protection from TNFa-dependent death
(Fig. 2C). Moreover, zVAD failed to block TNFa-induced ROS
accumulation in TAK1 KO cells (Fig. 2D). Similar observations
were obtained by using another broad-spectrum caspase
inhibitor, Q-VD-OPh (Fig. S1). These results indicate that
TNFa-dependent caspase activation plays only a marginal role
in the death of TAK1 KO cells. Of note, Nec-1 and BHA
treatment attenuated caspase-8 and caspase-3 cleavage follow-
ing stimulation, indicating that TNFa-induced ROS accumu-
lation augmented caspase activation (Fig. 2E) [18]. Nec-1 and
BHA provided full protection from TNFa-mediated rapid cell
death without a complete block on caspase activation (Figure 1C
and 2E), further supporting the conclusion that ROS-mediated
necrosis is the primary cause of the rapid demise of TNFa-
stimulated TAK1 KO cells, giving no time to caspase-
dependent apoptotic processes to mediate cell death.
TAK1 blocks TNFa-dependent necrosome formation
TNFa-mediated necrotic cell death requires the formation of
the necrosome complex, including RIP1, RIP3, FADD and
caspase-8, whose catalytic activity has to be blocked by either
small-molecule inhibitors or virally expressed anti-apoptotic
proteins [1,3]. Using FADD immunoprecipitation, we investi-
gated whether TNFa could induce necrosome formation in the
absence of TAK1. As expected, WT MEFs required co-
administration of zVAD together with TNFa and CHX for
efficient necrosome formation (Fig. S2). On the other hand, in
TAK1 KO cells, all known components of the necrosome
complex immunoprecipitated with FADD within 30-45 min-
utes of TNFa stimulation (Fig. 3A). Necrosome formation was
fully inhibited by Nec-1 treatment, implicating an absolute
dependence on catalytically active RIP1 (Fig. 3B). Thus, our
study presents TAK1 as a key mediator of TNFa signalling that
specifically blocks RIP1 kinase activity-dependent necrosome
formation.
Surprisingly, in both WT and TAK1 deficient MEFs, the
necrosome complex contained cFLIPL (Fig. 3A, 3B and Fig. S2).
Given its dual nature on the modulation of caspase-8 activation
[13], further analysis of cFLIPL within the necrosome complex
may shed light on the dynamics of necrosome formation and
function.
It is of note that at later time points, predominantly the cleaved
forms of caspase-8 and cFLIPL (43 kDa) were found in the
necrosome complex, although the p43 fragment of caspase-8 was
poorly identifiable in input samples (Fig. 3A and 3B). This
indicated that caspase-8 in the necrosome was catalytically active
and processed itself as well as cFLIPL. Accordingly, treatment of
TAK1 KO MEFs with TNFa and zVAD enhanced the
incorporation of full length caspase-8, cFLIPL and RIP1
(Fig. 3B). Whether this translates into an enhanced activation of
the necrosome complex is an open question, nevertheless, these
experiments show that RIP1 kinase activity-dependent necrosome
formation can occur in the presence of ongoing caspase activity.
Also, caspase-8-mediated cleavage and the assumed inactivation of
RIP1 (Fig. 2A) [1,3] does not block programmed necrosis initiation
following TNFa stimulation.
TAK1 stabilizes Ubi-RIP1 association with complex-I
In order to analyze whether TAK1 curbs the cytotoxic potential
of RIP1 by regulating its incorporation into TNFa-induced
complex-I, WT and TAK1 KO MEFs were stimulated with
Flag-TNFa and complex-I was immunoprecipitated with an a-
Flag antibody. Stimulus-dependent incorporation of Ubi-RIP1
[7,24] into complex-I was evident in both cell types, yet in TAK1
KO cells, the amount of Ubi-RIP1 decreased significantly at later
time points compared to WT cells (Fig. 3C), indicating that TAK1
stabilizes Ubi-RIP1 in complex-I. In TNFa-treated TAK1 KO
cells, the accelerated dissociation of RIP1 from complex-I was
accompanied by RIP1-dependent necrosome formation within
30 minutes of stimulation. Hence, TAK1-mediated protection of
cells from TNFa-induced rapid cytotoxicity might proceed via
regulation of ubiquitinated-RIP1 incorporation into complex-I. In
a similar manner, it has been shown that treatment of cells with
Smac mimetic to diminish cIAP1/2 expression and Ubi-RIP1
association with complex-I also resulted in RIP1 kinase-activity-
dependent caspase activation and subsequent cell death following
TNFa stimulation [7].
TAK1 Dictates TNFa-Dependent RIP1 Function
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TAK1 has a kinase-independent cytoprotective function
In order to ensure that the sensitivity of TAK1 KO MEFs to
TNFa-induced cytotoxicity was only due to the lack of TAK1
expression, cells were stably transfected with wild type TAK1.
TAK1 KO MEFs were also reconstituted with a catalytically
inactive mutant of TAK1 (TAK1-K63W [25]) to investigate
Figure 1. TAK1 impairs ROS-mediated cell death triggered by catalytically active RIP1. (A) Left panel TAK1 KO MEFs transfected with a
control siRNA (siC) or with RIP1 targeting siRNAs were stimulated with TNFa and cell survival was analyzed by crystal violet staining (CV). The bar
graphs depict mean values 6 SEM %. Right panel Cell lysates were analyzed by western blotting (WB) with a-RIP1 and a-NEMO antibodies to control
the efficiency of RIP1 down-regulation. (B) TAK1 KO MEFs were transfected as in (A) and stimulated with TNFa. Intracellular ROS accumulation was
analyzed by flow cytometry. (C) TAK1 KO MEFs were treated with DMSO or Necrostatin-1 (Nec-1) for 1 hour and then stimulated with TNFa. Butylated
hydroxyanisole (BHA) was added together with TNFa. Cell survival was analyzed by CV. The bar graphs depict mean values 6 SEM %. (D) TAK1 KO
MEFs were treated with DMSO, Nec-1 or BHA as in (C) and stimulated with TNFa for indicated time points. ROS accumulation was analyzed as in (B).
doi:10.1371/journal.pone.0026069.g001
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whether TAK1 kinase activity was required for the protection
from necrosis. By using a TAK1 kinase inhibitor (NP-009245) at
1 mM, it has been suggested that inhibition of TAK1 catalytic
activity further increased caspase-independent necrosis in L929
cells [21]. However, at this concentration, NP-009245 inhibited
EGF and PMA-mediated JNK phosphorylation in WT and TAK1
KO MEFs equally well, indicating that NP-009245 did not
enhance TNFa-mediated necrosis specifically via TAK1 inhibition
(Fig. S3).
As expected, TAK1 KO cells reconstituted with TAK1-WT
were capable of TNFa-induced IkBa degradation, which was
impaired in cells expressing TAK1-K63W (Fig. 4A). Nevertheless,
reconstitution of TAK1 KO cells with either construct resulted in
a prolonged association of Ubi-RIP1 with TNFa-induced
complex-I compared to empty vector-transfected cells (Fig. 4B).
This suggested a scaffold function for TAK1 to restrict the
premature dissociation of RIP1 from complex-I. In parallel with
this observation, TNFa-dependent necrosome formation was
inhibited upon reconstitution with either TAK1-WT or TAK1-
K63W (Fig. 4C). Moreover, expression of TAK1-WT or TAK1-
K63W in TAK1 KO cells provided complete protection from
TNFa-dependent cytotoxicity (Fig. 4D) and also blocked TNFa-
induced caspase activation (Fig. 4E) as well as ROS accumulation
(Fig. 4F). These data demonstrate that TAK1 acts as an adaptor
molecule in complex-I to prevent premature dissociation of Ubi-
RIP1 and also functions independently of its kinase activity to
block TNFa-induced, RIP1-mediated necrosis. Therefore, our
data suggest that TAK1 may suppress the pro-necrotic activity of
RIP1 by sequestering it within complex-I, highlighting a novel
non-catalytic function of TAK1 in complex-I in addition to its role
as a signal transducer for TNFa-mediated NF-kB activation.
RIP1-dependent necrotic cell death is not only observed
following death receptor stimulation, but also in acute pancreatitis
[9,10], ischemia-induced brain injury [23] as well as myocardial
infarction [26]. Hence, future studies may reveal whether TAK1
also modulates RIP1-dependent necrosis under these pathophys-
iological conditions and help further characterization of TAK1-
RIP1 interplay in necrotic cell death.
Materials and Methods
Reagents and cytokines
Recombinant human TNFa and Flag-TNFa (Alexis) were used
at 20 ng/ml and 200ng/ml, respectively. Nec-1 (Biomol), BHA
(Sigma), zVAD(oMe)-FMK (Imgenex) and Q-VD-OPh (Calbio-
chem) were utilized at 10 mM, 100 mM, 20 mM and 20 mM,
Figure 2. TNFa-induced caspase activity in TAK1 deficient cells is not essential for ROS-mediated cytotoxicity. (A) TAK1 KO and WT
MEFs were stimulated with TNFa as indicated and analyzed by WB with the indicated antibodies to detect IkBa degradation and the cleavage of RIP1,
caspase-8 (p18) and caspase-3 (p15). (B) TAK1 KO MEFs were pre-treated with DMSO or zVAD for 1 hour, stimulated with TNFa and analyzed by WB
for cleaved caspase-8, caspase-3 and IKKb. (C) TAK1 KO MEFs were pre-treated as in (B) and stimulated with TNFa. Cell survival was analyzed by CV.
The bar graphs depict mean values 6 SEM %. (D) TAK1 KO MEFs were pre-treated as in (B) and stimulated with TNFa. ROS accumulation was
evaluated by flow cytometry. (E) TAK1 KO MEFs were pre-treated with DMSO or Nec-1 for 1 hour, stimulated with TNFa and analyzed as in (B). BHA
was added together with TNFa. (*) denotes the cleaved fragments of caspase-3 (p15) and RIP1.
doi:10.1371/journal.pone.0026069.g002
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respectively. TAK1-inhibitor (NP-009245) was purchased from
AnalytiCon Discovery. EGF (Invitrogen) and PMA (Calbiochem)
was used at 25 ng/ml and 300 ng/ml, respectively.
Antibodies
The following antibodies were used for immunoprecipitation and
western blot analyses: RIP1 (clone 38) and NEMO (clone 54) from
BD Transduction, TAK1 (M-579), FADD (M-19), TRAF2 (C-20)
and IkBa (C-21) from Santa Cruz Biotechnology, IKKb (A10AG2)
from Millipore, cleaved caspase-8 (#9429), caspase-3 (#9662) and
p-JNK (#9251) from Cell Signaling, JNK (51-1570GR) from BD
Pharmingen, caspase-8 (1G12) and c-FLIPL (Dave2) from Enzo Life
Sciences, RIP3 (2283) from Proscience, TNF-RI (ab 19139) and
TRADD (ab 18914) from Abcam. Rabbit polyclonal antibody
against PARP1 (288) was described previously [27].
DNA and siRNA constructs
Murine TAK1-WT and K63W were subcloned into pTRA-
CER-CMV2 (Invitrogen) from pCMV-HA-TAK1-WT and
K63W constructs (gift from Dr. Kunihiro Matsumoto, Nagoya
Figure 3. TAK1 prevents TNFa-induced necrosome formation and stabilizes polyubiquitinated RIP1 in complex-I. (A) TAK1 KO MEFs
were stimulated with TNFa and lysed for immunoprecipitation with an a-FADD antibody to isolate the necrosome complex. Co-immunoprecipitated
proteins were analyzed by WB with the indicated antibodies. (B) TAK1 KO MEFs were pre-treated with DMSO, Nec-1 or zVAD for 60 minutes and then
stimulated with TNFa. Cell lysates were analyzed by WB as in (A). (C) WT and TAK1 KO MEFs were stimulated with Flag-TNFa for indicated time points.
TNFa-bound TNF-RI and additional complex-I members were immunoprecipitated by a-Flag M2 affinity beads and analyzed by WB. Ubi-RIP1 depicts
complex-I-associated polyubiquitinated RIP1. (*) denotes the p43 fragment of caspase-8 and cFLIPL. n.s, non-specific band.
doi:10.1371/journal.pone.0026069.g003
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Figure 4. TAK1 blocks TNFa-induced necrosis independently of its kinase activity. (A) TAK1 KO MEFs transfected with a WT or a kinase-
dead mutant (K63W) construct of TAK1 along with untransfected and empty-vector (EV) transfected cells were stimulated with TNFa and analyzed by
WB for IkBa degradation as well as TAK1 and NEMO expression. (B) Cells were stimulated with Flag-TNFa and Ubi-RIP1 interaction with complex-I was
TAK1 Dictates TNFa-Dependent RIP1 Function
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University, Nagoya, Japan) between KpnI/XbaI restriction sites.
RIP1 expression was downregulated by using two different siRNA
constructs (#1 sense: 59 GCAGAGAGCUCGUGAGAAU 39 and
#2 sense: 59 CCACUAGUCUGACUGAUGA 39). Non-targeting
control siRNA construct was 59 UCAAAUUGGUCCACGGAUA
39. All siRNA duplexes were purchased from Eurogentec.
Cell culture and transfections
WT and TAK1 KO MEF cells [19] were a gift of Dr. Shankar
Ghosh (Columbia University, New York, USA) and maintained in
DMEM-GlutaMAX (Gibco) supplemented with 10% FCS (Gibco)
and penicillin/streptomycin (100 U/ml and 100 mg/ml). To
reconstitute TAK1 deficient MEFs with pTRACER-TAK1-WT
and pTRACER-TAK1-K63W along with empty pTRACER for
empty vector transfection, cells were transfected by using
Transfectin (Biorad) reagent according to manufacturer’s instruc-
tions. Stably transfected monoclonal cells were selected with 80–
100 mg/ml Zeocin (Invitrogen) and expanded for experimentation.
To downregulate protein expression, cells were transfected with
different siRNA (10–20nM) constructs with the help of lipids from
Silence Therepeutics according to manufacturer’s instructions and
harvested 3 days after transfection. All cells were starved overnight
before analysis.
Immunoprecipitation and western blotting
The necrosome complex was isolated as described previously
[8]. Briefly, cells (,1x107) were lysed in 1 ml necrosome buffer
(20 mM Tris-HCl 7.5, 150 mM NaCl, 0.2% NP-40, 1mM EDTA,
10% glycerol, 3 mM NaF, 1 mM b-glycerophosphate, 1 mM
Na3VO4, 50 nM Calyculin A (Cell Signaling), 500 mM Pefablock
(Roche) and protease inhibitor cocktail tablets (Roche)). Cleared
lysates were incubated with a-FADD antibody for 2 hours and
immunocomplexes were precipitated with protein G sepharose
beads (GE Healthcare) for another hour. Co-precipitated proteins
were analyzed by western blotting (WB). Standard procedures
were followed for WB.
Flag-TNFa immunoprecipitation was done as described
previously [24] with minor modifications. After stimulation with
200 ng/ml Flag-TNFa, cells (,1x107) were lysed in 500 ml Flag-
IP buffer (30 mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM EDTA
pH 8.0, 1 mM KCl, 1% Triton X-100, 8 mM b-glycerophos-
phate, 20 mM NaF, 200 mM Na3VO4, 500 mM Pefablock and
protease inhibitor cocktail tablets). Cleared lysates were incubated
with a-Flag-M2 affinity gel (Sigma) for 3 hours. For uninduced
samples, 200 ng of Flag-TNFa was added to the lysates just before
immunoprecipitation. Immunocomplexes were analyzed by WB.
Intracellular ROS measurement with carboxy-H2DCFDA
and Propidium Iodide staining
MEFs were stimulated for indicated time points and were
supplemented with 10 mM carboxy-H2DCFDA (Invitrogen) in the
last 30 minutes of incubation at 37uC. Cells were then trypsinized,
washed and re-suspended in 1 ml PBS. Intracellular ROS
accumulation was analyzed by using the FL1 channel of a BD
FACSCalibur flow cytometer. Propidium iodide (PI, Sigma) was
added (2 mg/ml) to each sample just before measurement. PI
staining was visualized by using the FL3 channel. Data was
analyzed by using FlowJo software. In all experiments, cells were
FSC/SSC gated before analysis. ROS accumulation was visual-
ized in the living population (PI negative cells).
Crystal violet staining (CV)
Following medium removal, MEFs (in 12-well plates) were
incubated for 5 minutes with 1 ml PFA/PBS (4%, RT). PFA/
PBS was replaced by 1 ml of 0.01% CV solution (Sigma, in
ddH2O) and incubated for 20–30 minutes. Plates were washed
3–4x with tap water and let dry briefly. CV was solubilised with
methanol, and its absorbance was measured at 540 nm. All
treatments were done in at least triplicates. The graphs depict
mean values 6 SEM %.
Supporting Information
Figure S1 Caspase inhibition by Q-VD-OPh does not
block TNFa-induced ROS accumulation and death in
TAK1 KO MEFs. (A) TAK1 KO MEFs were pre-treated with
DMSO, Q-VD-OPh (20 mM) or zVAD-FMK (20 mM) for one
hour and then incubated with or without TNFa for another hour.
The efficiency of caspase inhibition was assessed by WB analysis of
cleaved PARP1 and RIP1. (*) denotes the cleaved products of
PARP1 and RIP1 (B) TAK1 KO MEFs were pre-treated with
DMSO or Q-VD-OPh (20 mM) for one hour and then stimulated
with TNFa as indicated. ROS accumulation was analyzed by flow
cytometry. (C) TAK1 KO cells were pre-treated as in (A) and (B),
and stimulated with TNFa for 3 hours. Cells were stained with
propidium iodide (PI) and analyzed by flow cytometry. The
percentage of dead (PI positive) cells is indicated in each
histogram.
(TIF)
Figure S2 TNFa-induced necrosome formation in WT
MEFs requires inhibition of protein synthesis and
caspase activity. WT MEFs were pre-treated for 1 hour with
cycloheximide (CHX (Sigma), 1 mg/ml) and/or zVAD (20 mM) as
indicated and stimulated with TNFa for 4 hours. Necrosome
formation was evaluated by WB analysis with the indicated
antibodies following a-FADD immunoprecipitation.
(TIF)
Figure S3 Limited specificity of the TAK1 inhibitor NP-
009245. (A) WT and TAK1 KO MEFs were pre-treated with
DMSO or NP-009245 (denoted as NP, 1 mM) for 1 hour and
stimulated with EGF (25 ng/ml) or PMA (300 ng/ml) for
15 minutes. The inhibitory effect of NP-009245 was investigated
by WB analysis of stimulus-dependent JNK phosphorylation,
which was efficiently blocked in both TAK1 KO and WT MEFs.
(B) WT MEFs were pre-treated with DMSO or increasing
concentrations of NP-009245 for 1 hour and subsequently
incubated with TNFa for 15 minutes. The inhibitory effect of
NP-009245 on TAK1 catalytic activity was evaluated by WB
analyses of IkBa degradation and JNK phosphorylation. 50 nM of
NP-009245 was sufficient to block TNFa-induced JNK phosphor-
ylation; while IkBa degradation was only blocked at 1 mM (C) WT
MEFs were pre-treated as in (B) and then stimulated with TNFa
for 3 hours. Cell survival was analyzed by cystal violet staining.
NP-009245 induced cell death already at 250 nM. (D) WT MEFs
analyzed by immunoprecipitating Flag-TNFa-bound TNF-RI and associated factors by a-Flag M2 affinity beads as in Fig. 3C. (C) Indicated cells were
stimulated with TNFa and necrosome formation was investigated by immunoprecipitating FADD as in Fig. 3A and 3B. (D) Cells were stimulated with
TNFa and cell survival was analyzed by CV. The bar graphs depict mean values 6 SEM %. (E) Cells were stimulated with TNFa and caspase activation
was assessed by WB analysis. (F) Cells were treated with TNFa and intracellular ROS accumulation was analyzed by flow cytometry. (*) denotes the
p43 fragment of caspase-8 and cFLIPL. (#) denotes cleaved caspase-3 (p15). n.s., non-specific band.
doi:10.1371/journal.pone.0026069.g004
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were pre-treated as in (B) and stimulated with TNFa for 1 hour.
Cells were lysed and immunoprecipitated with an a-FADD
antibody to subsequently analyze RIP1 co-immunoprecipitation.
Weak RIP1 co-immunoprecipitation with FADD was only
observed at 1 mM of NP-009245.
(TIF)
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